Effectiveness of topical 2% tranexamic acid in the management of melasma
DOI:
https://doi.org/10.66344/jpad.v31i3.1761Abstract
Background Melasma is an important issue among the society that severely affects the skin. Hence, there is effort on regular basis from health care provider to find the best remedy for this disease.
Methods This is an experimental study done in the Dermatology department, Lahore general hospital (LGH), Lahore. After taking ethical approval letter from hospital ethical committee, consent was taken from all enrolled melasma patients. Both gender and age between 19 to 45years were selected. All the patients were assessed for baseline MASI score using the MASI questionnaire. Topical 2% tranexamic acid was given to the patients and they were told to keep away from sun light and apply sunblock cream SPF60. Clinical examination, photographs of affected area (Hiding the patient’s identity) and MASI scoring was carried out after 12 weeks of treatment to determine the efficacy as per operational definition. The clinical outcome was recorded on proforma. Data was analyzed using SPSS 20.
Results There were total 120 cases of mean age 30.01±6.26 years. 64 (53.33%) were male cases and 56 (46.66%) were female cases. Baseline MASI score was 24.50±4.14, and after 2% tranexamic acid was 23.85±3.90. With respect to efficacy, it was noted that 86 (71.66%) attained positive response from 2% tranexamic acid with significant improvement in males.
Conclusion Topical 2% tranexamic acid is the effective treatment in the management of melasma.
References
1. Aamir S, Naseem R. Oral tranexamic acid in treatment of melasma in Pakistani population: a pilot study. J Pak Assoc Dermatol.2016;24(3):198-203.
2. Thoyyib M, Menon R, David BG. Clinical spectrum of facial hypermelanosis: a descriptive study from a tertiary care center. Intern J Res.2020;6(2):212.
3. Kaleem S, Ghafoor R, Khan S. Comparison of efficacy of Tranexamic Acid Mesotherapy versus 0.9% normal Saline for Melasma; A split face study in a Tertiary Care Hospital of Karachi. Pak J Med Sci. 2020;36(5):930.
4. Pandey S, Sharma N, Pokhrel K. Dermatological Conditions Associated with Pregnancy: A Hospital Based Study. J Nepalgunj Med Coll.2019;17(1):23-7.
5. Kunninpuram RM, Joy B, Mathew P, Sridharan R, Thyvalappil A, Krishnanpotty R. A clinico-epidemiological study of melasma in a tertiary care hospital: A cross sectional study. J Pak Assoc Dermatol. 2020;30(2):310-5.
6. Cestari T, Peruzzo J, Giongo N. Definition, incidence, and etiology of melasma and vitiligo in brown skin. Springer, New Delhi. 2017; 13-19.
7. Levoska MA, Mohammad TF, Hamzavi IH. Lasers in Pigmentary Skin Disorders. Springer, Cham. 2018;209-33.
8. Naqvi F, Imran I, Faraz AA, Tabussam T, Sikandar S. A double blind study to compare the efficacy of Aloe vera gel and undecylenoyl phenylalanine 2% for treatment of melisma. Prof Med J. 2020;27(08):1770-6.
9. Handel AC, Miot LD, Miot HA. Melasma: a clinical and epidemiological review. An Bras Dermatol.2014;89(5):771-82. doi: 10.1590/abd1806-4841.20143063. PMID: 25184917; PMCID: PMC4155956.
10. Swope VB, Abdel-Malek ZA. MC1R: Front and center in the bright side of dark eumelanin and DNA repair. Intern J Molecul Sci.2018;19(9):2667.
11. Rodrigues M, Pandya AG. Melasma: clinical diagnosis and management options. Australasian J Dermatol.2015;56(3):151-63.
12. Kim DG, Nam SM, Shin JS, Park ES. Effectiveness of the Pico-toning Technique for the Treatment of Melasma with a Low Fluence 1,064-nm Nd: YAG Laser in Asian Patients. Med Lasers.2020;9(2):166-71.
13. Batory M, Rotsztejn H. Topical Formulations and Intradermal Injections of Tranexamic Acid in the Treatment of Hyperpigmentation-A Review. Letter Drug Design Discov.2018;15(2):212-8.
14. Saleh FY, Abdel-Azim ES, Ragaie MH, Guendy MG. Topical tranexamic acid with microneedling versus microneedling alone in treatment of melasma: clinical, histopathologic, and immunohistochemical study. J Egypt Women’s Dermatol Soc. 2019;16(2):89.
15. Atefi N, Dalvand B, Ghassemi M, Mehran G, Heydarian A. Therapeutic effects of topical tranexamic acid in comparison with hydroquinone in treatment of women with melasma. Dermatol Ther.2017;7(3):417-24.
16. Sahu PJ, Singh AL, Kulkarni S, Madke B, Saoji V, Jawade S. Study of oral tranexamic acid, topical tranexamic acid, and modified Kligman's regimen in treatment of melasma. J Cosm Dermatol.2020;19(6):1456-62.
17. Kim SJ, Park JY, Shibata T, Fujiwara R, Kang HY. Efficacy and possible mechanisms of topical tranexamic acid in melasma. Clin Exp Dermatol.2016; 41(5):480-5.
18. Sarkar R, Ailawadi P, Garg S. Melasma in men: A review of clinical, etiological, and management issues. J Clin Aesthetic Dermatol.2018;11(2):53.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 DR ZAHEER SALEEM, DR ATIF SHEHZAD, DR ABEER,, DR KEHKSHAN TAHIR,, DR SAADIYA SIDDIQUI, DR UZMA AMIN AMIN
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
